Luo X; Yu Ji-Xian, Xie L, Ma Wen-Jun, Wang Li-Hong

Language: English
References: 20
Page: 888-892
PDF size: 132.78 Kb.

ABSTRACT

Purpose. This study aims to investigate the antiviral effect of polyethylene glycol (PEG)-interferon α-2a and PEG-interferon α-2b treatment on hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) at the 48th week of treatment and the 24th and 48th week after withdrawal, in order to provide guidance on the antiviral treatment of HBeAg-positive CHB patients. Material and methods. Antiviral treatment was performed on 155 HBeAg-positive CHB patients. Among these patients, 66 patients received PEG-interferon α-2a treatment and 89 patients received PEG-interferon α-2b treatment; and these treatments were administered by subcutaneous injection, once per week, which lasted for 48 weeks. Other antiviral and hepatoprotective drugs were not used during the treatment. Results. At the 48th week of treatment, ALT recovery rate, HBsAg seroconversion rate, HBeAg seroconversion rate and HBV DNA titers dropped below 200 IU/mL rate were 69.7%, 6.1%, 27.3% and 50.0%, respectively, in the PEG-interferon α-2a group; and were 70.8%, 6.7%, 33.7% and 62.9%, respectively, in the PEG-interferon α-2b group. At the 24th and 48th week of follow-up after withdrawal, HBsAg seroconversion rate in these two groups did not change; and HBeAg seroconversion rate further increased. Furthermore, HBV DNA revealed a low recurrence rate. The difference between these two groups was not significantly significant. Conclusions. PEG-interferon α-2a and PEG-interferon α-2b are effective antiviral drugs for the treatment of HBeAgpositive CHB, which has a HBsAg seroconversion rate of more than 5%. Furthermore, this sustained response effect was maintained at the 24th and 48th week of follow-up after withdrawal.

REFERENCES

1. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39(3): 857-61.

2. Lai CL, Ratziu V, Yuen MF, Thierry P. Viral hepatitis B. Lancet 2003; 362(9401): 2089-94

3. Chen Y, Chen YP, Tao RF. The research progress of chronic hepatitis B. China Medicine 2011; 6(4): 500-2.

4. Ren X, Xu Z, Liu Y, Li X, Bai S, Ding N, Zhong Y, et al. Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. J Viral Hepatology 2010; 17(12): 887-95.

5. Jiang ZW and Liu X. The study of the consequence about α- interferon and Hepatitis B virus genotype of B and C on the treatment of chronic Hepatitis B. Modern Medicine 2013; 41(3): 205-7.

6. Zhang WW, Han ZY. The study of the consequence about acupoint injection α-interferon on the treatment of chronic Hepatitis B. China’s health care nutrition 2012; 2(7): 1767-8.

7. Li WL, Wu MS, Huang YB. The expression of peripheral blood mononuclear cells TLR4 and the change of serum type Th1/Th2 cytokines on the α-interferon treatment of chronic Hepatitis B. Practical Hepatology 2012; 15(4): 315-17.

8. Chinese Society of Hepatology and Chinese Society of Infectious Diseases: The guideline of prevention and treatment of chronic hepatitis B (2010). Chin J Hepatol 2011; 19(1): 13-24.

9. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2001; 120: 1828-53.

10. Li HQ, Li H. The antiviral mechanism and effect of interferon on viral hepatitis. China Public Health 2005; 22(7): 890-91.

11. Xu BF, Fan QL, Wei W, Song LH. The advance of the antihepatitis virus mechanisms about α-interferon and peg-interferon. Chinese Pharmacological Bulletin 2008; 14(10): 1276-9.

12. Lin Q, Yu XP, Su ZJ. The curative effect analysis of partial response of nucleoside analogues on the treatment of chronic hepatitis B to continue with the alpha interferon. Practical Hepatology 2013; 16(3): 232-4.

13. You CY. Analysis of the adverse drug reactions of α-interferon on the treatment of chronic hepatitis B. Clinical rational Drug Use 2013; 6(2): 53.

14. Li Z. The clinical observation of Peg-interferon α-2 a180 μg combined with adefovir on the treatment of chronic hepatitis B. The latest medical information abstract 2012; 12(10): 267-268.

15. Shi YY. The clinical observation of peg-interferon compared with conventional interferon on treatment of 60 cases of chronic hepatitis B. Public Medical Forum 2015; 19(5): 640-2.

16. Wang Y, Liu SM. The research of the side effects and clinical significance of alpha interferon on the treatment of chronic hepatitis B. Chin J Biochem Pharm 2014, 7(34): 126-8.

17. Chen YF, Zhang W, Qiu LL. The effect comparison of Peg-interferon with conventional interferon on treatment of chronic hepatitis B. Clinical Medical 2013; 22(7): 94-5.

18. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, Chutaputti A, et al. Peginterferon α-2a(40 kDa): an advance in the treatment of hepatitis B e antigenpositive chronic hepatitis B. J Viral Hepatitis 2003; 10: 298-305.

19. Chan HL, Wong VW, Chim AM, Lai HC, Huang CF, Hsieh MY, Huang JF, et al. Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha-2a. Antiviral therapy 2008; 13: 555-62.

20. Tangkijvanich P, Komolmit P, Mahachai V, Sa-Nguanmoo P, Theamboonlers A, Poovorawan Y. Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon α-2b therapy in hepatitis B eantigen- positive chronic hepatitis B. Hepatology Research 2010; 40: 269-77.